Milestone Pharmaceuticals Inc. (MIST) stock
MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.66−0.01 (-1.06%)
Close on Nov 12, 2026Market cap $81.57MP/E –Yield –
Milestone Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Milestone Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$78.21M. For fiscal 2025 it was -$62.03M. The highest annual figure on record is -$23.81M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.03M | – |
| FY2024 | Dec 31, 2024 | -$42.00M | – |
| FY2023 | Dec 31, 2023 | -$61.01M | – |
| FY2022 | Dec 31, 2022 | -$59.55M | – |
| FY2021 | Dec 31, 2021 | -$42.98M | – |
| FY2020 | Dec 31, 2020 | -$50.61M | – |
| FY2019 | Dec 31, 2019 | -$57.84M | – |
| FY2018 | Dec 31, 2018 | -$23.81M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.48M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.78M | -2383.3% |
| Q1 FY2022 | Mar 31, 2022 | -$14.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.25M | – |
| Q2 FY2021 | Jun 30, 2021 | $735.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.73M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.25M | – |
See a number that looks wrong?